Ryan Mee, CEO of Fulcrum Metals, reviews FY23 and progress on the Gold Tailings Hub in Canada. Watch the video here.
Shivashares ,the link Matterhorn has just posted includes the detail:
Dr Dibyajyoti Karmakar - College of Medicine & Sagore Dutta Hospital
Department of General Medicine, 578, B.T.Road, Kamarhati, Kolkata-700058
Kolkata
karmakardibyajyoti @ gmail . com
Dr Anita Mathew - Fortis Hospitals Limited
Level 5, Clinical research department, Mulund Goregaon Link Road, Bhandup (W),400078
Mumbai
jojosanish @ gmail . com
Dr Yandrapati Gnana Sundara Raj - King George Hospital
Clinical Research Room, Department of General Medicine, Rajendraprasad Ward, Maharanipeta-530002
Visakhapatnam
drysundarrajuresearch @ gmail . com
Dr Arunansu Talukdar - Medical College and Hospital, Kolkata
Department of Medicine, 88, College Street, 700073
Kolkata
dratalukdar @ gmail . com
Dr Ashish Bhalla - Postgraduate Institute of Medical Education and Research
Department of Internal Medicine, Sector-12, 160012, India
Chandigarh
bhalla.chd @ gmail . com
Dr T Anil Kumar - Ramaiah Medical College
Department of Medicine Ramaiah Medical College, MSRIT Post,560054
Bangalore
buddhatozen4265 @ gmail . com
Dr Nirav Bhalani - Rhythm Heart Institute- A unit of SLPL
1st Floor, Clinical Research Department, Near Siddharth Bunglows, Sama-Savli Road, 390022
Vadodara
trial @ rhythmheart . com
Dr Kannan Rajendran - Saveetha Medical College Hospital
CRF-Department, Saveetha Nagar, Thandalam-602 105
Chennai
endork @ yahoo . com
Dr Prabhu Subramani - Victoria Hospital, Bangalore Medical College and Research Institute
Room 301. 3rd Floor, OPD Block, K.R.Road, Fort - 560002
Bangalore
drprabhusubramani @ gmail . com
Dr Namdev Sakharam Jagtap - Vishwaraj Superspeciality Hospital
Department of Medicine, Ground floor, OPD no 1 , Pune Solapur Road ,Near Loni railway station , Kadamwasti, 412201
Pune
drjagtapdev @ gmail . com
Firstly what a fantastic rise we've had today, confirmation that SNG001 is effective against variants. Even though many of us knew this would be the case its great to have some scientific evidence to back it up and with variants being a hot topic at the moment.
This totally slipped my mind and probably caught many of us off guard, I was just wondering when do we expect to have an update on long covid for our trial participants, I recall RM saying we would be updated about this when the data is ready. Another one to keep an eye out for.
GLA
Isn't this an Australian Radio station?
"About us: HPR is an internet only radio network that has been broadcasting globally with dedicated audio streams for Brisbane Sydney and Melbourne over the internet now for 2 years. It targets health professionals in hospital based environments but does not exclude other health professionals or the public from listening.."
"Given the Activ-2 entry criteria are wider, at least for the current P2, the hospitalisation rate may well be lower than for our home trial. "
I agree but this is a hurdle for all the treatments currently going through p2 of ACTIV2. A bonus we have is that we have supporting data on 120 patients from our SG016 home arm so in total they will have data on 340 patients who trialled the drug in a home setting. 220 in A2 and 120 in SG016. Hospitalisation rate will be low as most would have recovered on their own but this is something the brainboxes will factor in surely.
Hoping for progression to p3 with and adapted protocol targeting a more specific cohort such as the breathless .
Geo, we are being trialled in ACTIV-2 (outpatient treatments) and currently in phase 2, hopefully we will progress to phase 3.
ACTIV-3 is for inpatient treatments, which we are not participating.
GLA
SP would be nice, but would have thought with approvals in place in markets such as US/UK, the SP would be quite higher than £2. That would be disappointing. Hopefully we have long awaited ACTIV-2 update which should hopefully shift market sentiment and put as back on a good trajectory to around SP of 1.75 .